APBR-3 is under clinical development by Aprilbio and currently in Phase I for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease). According to GlobalData, Phase I drugs for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APBR-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APBR-3 overview
APBR-3 is under development for the treatment of autoimmune disorders inflammatory bowel disease, rheumatic arthritis, inflammatory diseases and adult onset still’s disease. The drug candidate is a recombinant anti-serum albumin Fab-IL-18 binding protein (BP) fusion protein.
Aprilbio overview
Aprilbio is a Korean based bio pharmaceutical manufacturing company. The company is involved in the manufacture of innovative bio drugs based on antibody drug fragments. Aprilbio has four pipe line products(APB-A1, APB-R3, APB-A2, APB-R2). The company collaborates with horizon, Samsung Biologics, Sartorius, SNBL, Charles river, DaHyun TAX and BINEX. Aprilbio owns a long acting protein medicine platform technology using FAB antibody parts to make serum albumin and EX-12 Helper Phage antibody library technology. Aprilbio is headquartered in Gangwon-do, Province of South Korea.
For a complete picture of APBR-3’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
